INTRODUCTION
Adverse interactions between two or more medications have been a longstanding problem in clinical practice. Such interactions frequently result from one drug impairing the elimination of another, which can lead to increased systemic concentrations of the affected drug and the potential for an adverse or toxic reaction. The cytochrome P450 3A (CYP3A) subfamily, consisting primarily of CYP3A4 and CYP3A5 in adults, is believed to participate in the metabolism of over half of therapeutic agents that undergo oxidation (Wilkinson, 2005) . Taken together, inhibition of CYP3A-mediated metabolism is a common mechanism underlying numerous drug-drug interactions. In addition, the extent of inhibition of CYP3A-mediated drug clearance by a co-medicant often varies between individuals, making it difficult to predict the magnitude and severity of the interaction.
Both CYP3A4 and CYP3A5 are expressed primarily in the liver and small intestine.
Although >30 allelic variants in the CYP3A4 gene have been identified, low variant frequencies, often combined with a lack of functional consequence, indicate a limited contribution by these variants to the large interindividual variation observed in CYP3A4 expression Wojnowski, 2004) . In contrast, CYP3A5 expression is clearly polymorphic, and the frequency of robust expression of a functionally significant protein results from genetic mutations that vary among different ethnic groups Xie et al., 2004) . For example, CYP3A5 protein has been detected readily in liver specimens obtained from 10-40% of various European and North American Caucasian individuals, 33% of Japanese individuals, and 55% of African Americans . Although CYP3A4 generally represents the dominant CYP3A enzyme in the liver, CYP3A5 can represent more than 50% of total hepatic CYP3A content in some individuals (Kuehl et al., 2001; Lin et al., 2002) .
Inheritance of at least one copy of the reference CYP3A5 allele (CYP3A5*1) confers CYP3A5 expression, whereas inheritance of two copies of a variant allele (CYP3A5*3) confers undetectable or very low CYP3A5 expression (Kuehl et al., 2001) . Consistent with the varying DMD #18382 5 frequencies of CYP3A5 expression, the frequency of CYP3A5*3 ranges from 85-95% in Caucasians, from 65-85% in Chinese and Japanese individuals, and from 27-55% in African Americans Xie et al., 2004) . In addition to CYP3A5*3, two other variants, CYP3A5*6 and CYP3A5*7, are associated with reduced CYP3A5 expression and are more common in individuals of African origin (2-17%) compared to Caucasians and Asians (<2%) Xie et al., 2004) . Accordingly, all three variants should be considered in any genotyping-based prediction of CYP3A5 function in populations of African origin (Hustert et al., 2001 ).
CYP3A4 and CYP3A5 share most of the same substrates (Huang et al., 2004) , and in vitro investigations have indicated that CYP3A5 can be less susceptible to inhibition than CYP3A4. Early examples involved the antifungal agents ketoconazole and fluconazole (Gibbs et al., 1999) . Using recombinant CYP3A enzymes and midazolam as the substrate, the K i of ketoconazole towards CYP3A5 was fourfold greater than that towards CYP3A4 (110 vs. 27 nM); an even greater difference was observed for fluconazole (85 vs. 9 µ M). A weaker inhibitory potency toward CYP3A5 compared to CYP3A4 was reported subsequently for other clinically relevant inhibitors including diltiazem, nicardipine, and mifepristone (Jones et al., 1999; McConn et al., 2004) . These observations suggest that genotypic differences in susceptibility to CYP3A inhibition could explain in part the large interindividual variation in the extent of inhibition of drug clearance by drugs and other xenobiotics.
A caveat to the aforementioned inhibitory differences between the CYP3As is that only midazolam was used as the CYP3A probe. In vitro evidence suggests that the extent of inhibition of CYP3A activity varies with substrate (Kenworthy et al., 1999; Stresser et al., 2000; Wang R et al., 2000) . This variation is explained in part, at least for CYP3A4, by the existence of multiple binding domains within the enzyme active site (Hosea et al., 2000; Schrag and Wienkers, 2001) . Midazolam, testosterone, and nifedipine appear to bind to different domains and are representative of three distinct substrate subgroups (Kenworthy et al., 1999) . The use 
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6 of at least two representative CYP3A substrates has been recommended for both the in vitro and in vivo evaluation of the inhibitory potential of drugs and other xenobiotics (Kenworthy et al., 1999; Yuan et al., 2002) .
To our knowledge, a systematic in vitro-in vivo correlation regarding inhibitor potency towards different CYP3A substrates in humans with different CYP3A5 genotypes has not been evaluated. Accordingly, the objectives of the current work were to determine the inhibitory potency of fluconazole towards two distinct probe substrates using pooled HLM with known CYP3A5 protein content and in healthy volunteers with known CYP3A5 genotype. Midazolam and erythromycin were selected as the substrates because both can be given safely and intravenously to humans. Fluconazole was selected as the inhibitor based on the 9-fold difference in inhibitory potency between recombinant CYP3As (Gibbs et al., 1999) ; minimal plasma protein binding; metabolism representing a minor route of elimination; a lack of effect on the efflux transporter P-glycoprotein (Venkatakrishnan et al., 2000) ; and a long elimination halflife in vivo (~30 hrs), which would provide a relatively stable concentration during the period of substrate elimination.
Gentest (Woburn, MA). A panel of 10 African American liver microsomal preparations (race/ethnicity supplied by the manufacturer) was purchased from Xenotech, LLC (Lenexa, KS). 
Characterization of Human Liver Microsomes for CYP3A Protein Content and

Susceptibility to Inhibition
Western blot analysis for CYP3A content. A panel of liver microsomes obtained from African American donors (n = 10) was characterized as described previously (Lyke et al., 2003) to generate two pools of HLM that contained either CYP3A4 or CYP3A5 as the major CYP3A
enzyme. Briefly, microsomes were diluted in sample buffer as described (Paine et al., 2005) 
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8 using the recombinant CYP3A enzymes (rCYP3As). The diluted microsomal preparations and reference standards were boiled (3 minutes), loaded onto 0.1% SDS-9% polyacrylamide gels (14 x 16 cm), and the proteins were separated by electrophoresis as described previously (Paine et al., 2005) . The proteins were transferred overnight to PVDF membranes at 4°C, after which the membranes were placed in blocking buffer [5% nonfat dry milk in phosphate buffered saline containing 0.3% Tween 20 (PBS-T)] at room temperature. After 1 hour, the blots were rinsed in PBS-T, then incubated with the anti-CYP3A4 (1:500) or anti-CYP3A5 (1:3000)
antibody. After 1 (anti-CYP3A4) or 2 (anti-CYP3A5) hours, the membranes were rinsed in PBS-T, incubated with the secondary antibody (1:500 x 1 hour for CYP3A4; 1:3000 x 2 hours for CYP3A5), and rinsed again. The proteins of interest were visualized by enhanced chemiluminescence using the Chemi-Doc imaging system (Bio-Rad, Hercules, CA). Integrated optical densities (IODs) were obtained using the Bio-Rad software program Quantity One (version 4.1). Calibration curves were generated by plotting the IODs of the reference standards against the mass of rCYP3A loaded. The amount of CYP3A enzyme/well was calculated relative to the calibration curve. Specific content was calculated by dividing the amount of enzyme/well by the amount of total microsomal protein loaded. The three preparations with undetectable CYP3A5 were pooled and designated as "CYP3A5 nonexpressors". The three preparations with the highest percent CYP3A5 content (with respect to total CYP3A content, CYP3A4+CYP3A5) were pooled and designated as "CYP3A5 expressors". Each pool was then analyzed for CYP3A4 and CYP3A5 content in the same manner as described for the individual preparations.
Inhibitory potency of fluconazole towards CYP3A catalytic activity. The inhibitory potency of fluconazole towards CYP3A activity (midazolam 1'-hydroxylation or erythromycin Ndemethylation) was evaluated using the CYP3A5-and CYP3A5+ HLM. For comparison, similar experiments were conducted with rCYP3As. Midazolam and fluconazole were dissolved in methanol to yield concentrated solutions ranging from 1-8 mM and 0.5-40 mM, respectively.
9 Erythromycin was dissolved in methanol to yield a 10 mM solution. To increase the sensitivity of the radiometric assay for determination of erythromycin N-demethylase activity (Lyke et al., 2003) the IC 50 , rather than K i , was determined. The highly sensitive radiometric assay for the determination of erythromycin N-demethylase activity has been described previously (Lyke et al., 2003) and was modified from a method by Riley and Howbrook (1997) . The amount of Envi-Carb solid phase extraction tubes (3 ml, 0.25 g) (Sigma-Aldrich). The tubes were eluted with 2 volumes of water (2 × 0.5 ml), which was transferred to scintillation vials containing 20 ml scintillation cocktail. The vials were placed in a PerkinElmer TRI-carb 2900T liquid scintillation analyzer, and the radioactivity was counted using a dual 3 H/ 14 C program (QuantaSmart 1.1 software, PerkinElmer). Research Advisory Committee at the University of North Carolina. To maximize the probability of identifying homozygous CYP3A5*1 carriers, only African American subjects were recruited.
Healthy unrelated volunteers, self-identified as African American or Black, provided mouthwash samples, from which genomic DNA was isolated using the QIAamp ® DNA blood mini kit (QIAGEN Inc., Valencia, CA).
Roughly equal numbers of volunteers genotyped as
CYP3A5*1/*1 (n = 6), "CYP3A5*1/*X" (n = 7), or "CYP3A5*X/*X" (n = 6) were enrolled in the pharmacokinetic study; in this context, "X" represents the CYP3A5*3, *6 or *7 allele. Individuals carrying two CYP3A5*1 alleles (CYP3A5*1/*1), or one CYP3A5*1 allele (CYP3A5*1/*X), were designated as CYP3A5 expressors. Individuals with two copies of the same defective allele (CYP3A5*X/*X) were designated as CYP3A5 nonexpressors. Individuals with two different defective alleles (CYP3A5*3/*6, CYP3A5*3/*7, or CYP3A5*6/*7) were excluded to avoid potential inference about the phenotype.
The participants, 13 women and 6 men, ranged in age from 18 to 45 years (average ± SD, 24 ± 8 years) and in weight from 57 to 97 kg (average ± SD, 76 ± 12 kg). Prior to enrollment, each subject presented for a screening visit that consisted of a medical history, physical examination, vital signs, and laboratory tests that included a complete blood count and blood chemistries (BUN, serum creatinine, AST, ALT, alkaline phosphatase, total bilirubin). All
This article has not been copyedited and formatted. The final version may differ from this version. of the women underwent a serum pregnancy test. None of the subjects was taking medications, prescription or non-prescription (including herbal products), known to alter CYP3A activity. All subjects were instructed to refrain from consuming grapefruit-containing products beginning at least one week before and during the course of the study, as well as to refrain from caffeinated and alcoholic beverages the evening before admission to the UNC General Clinical Research
Center (GCRC).
Determination of CYP3A5 genotype. CYP3A5 genotype was determined based on sequencing assays for the CYP3A5*3 (Kuehl et al., 2001) , CYP3A5*6 (14690G>A), and CYP3A5*7 (27131-32insT) variant alleles. PCR for CYP3A5*6 genotyping was performed using The second study phase (day 2) began the following morning, when the subject was given a single oral dose (400 mg) of fluconazole (Diflucan ® , Pfizer, New York, NY). Ninety minutes after fluconazole was given, the ERMBT was administered (at approximately the same time as on the previous day). Midazolam was given 30 minutes after [ 14 C Nmethyl]erythromycin injection (i.e., 120 minutes after fluconazole). Blood (10 ml) was collected through the indwelling catheter just before fluconazole administration, just before midazolam administration, and at 5, 10, 15, 45, 60, 120, 180, 240, 360, 480, 600 , and 720 minutes after midazolam administration. Plasma was separated from blood cells by centrifugation (3500 × g, 15 min, 4°C) and stored at -80°C pending analysis for fluconazole and midazolam. During both study phases, meals and snacks, which were devoid of grapefruit-containing products and caffeinated beverages, were provided after the 240-minute (4-hour) blood collection with respect to midazolam administration. Vital signs (blood pressure, pulse, respirations, temperature) were monitored periodically until the last blood collection, after which the subject was discharged.
Analytic Procedures
14 CO 2 in breath following ERMBT administration. The collected breath was bubbled, via a peristaltic pump, into a scintillation vial containing 4 ml of a CO 2 trapping solution (benzathonium hydroxide:absolute ethanol, 1:1) and the blue indicator dye, thymolphthalein (1%). When 2 mmol of CO 2 became trapped, as indicated when the blue dye turned clear, scintillation fluid (10 ml) was added, and 14 C specific activity was measured by scintillation counting. Results were expressed as the percentage of administered 14 C exhaled over the first hour post-injection, as estimated by a single breath collection at 20 minutes (Wagner, 1998) . Mobile phase A consisted of 40% methanol/40% acetonitrile/20% water, and mobile phase B consisted of 40% methanol/60% water. The initial conditions were 100% B at a flow rate of 0.7 ml/min, followed by a linear gradient to 100% A over 8 minutes. At 9 minutes, the flow rate was increased to 1.4 ml/min and held for 13 minutes, after which the flow rate was returned to 0.7 ml/min and 100% B over 1 minute. Fluconazole was detected by UV absorbance at 260 nm.
Midazolam in plasma following
The interday variation in the assay was 3.4% at 5.5 µ g/ml.
Pharmacokinetic Analysis and In Vitro -In Vivo Prediction of CYP3A Inhibition.
The pharmacokinetics of midazolam were evaluated using a noncompartmental approach (WinNonlin). The area under the plasma concentration vs. time curve (AUC) was determined using the log-linear trapezoidal method, and systemic clearance (Cl) was calculated as the ratio was calculated according to the following equation (Tucker, 1992; Yao et al., 2003) : 
The average inhibitor concentration after midazolam administration was calculated as AUC 120-840min /720 min. The high unbound fraction of fluconazole in plasma (~89%) was not considered in the calculation. Cl int,c and Cl int,i were determined by rearrangement of the well-stirred model for hepatic clearance:
where Q p and f u denote hepatic plasma flow and the plasma unbound fraction of midazolam (0.02), respectively. Q p was calculated using the measured hematocrit (Hcr) for each subject and the following equation: (0.02 l/min/kg × subject weight) × (1-Hcr). In addition, the mean intrinsic clearance in each genotype group was calculated from the mean blood clearance after conversion of plasma clearance to blood clearance using a midazolam blood-to-plasma ratio of was assumed to be equal to the IC 50 for a non-competitive inhibition mechanism (Kenworthy et al., 1999) , which was based on inhibition data involving fluconazole and the related CYP3A substrate cyclosporine (Omar et al., 1997) .
Statistical Analysis
The in vitro enzyme kinetic values are presented as means ± SEs of the parameter estimates. All statistical comparisons were made using SAS (version 9.1, SAS Institute Inc., The midazolam AUC and the ERMBT were adjusted for the logarithm of control values in order to appropriately account for baseline differences in these variables among subjects. 
RESULTS
Specific CYP3A4 and CYP3A5 content in pooled human liver microsomes. Based on the specific contents of CYP3A4 and CYP3A5 in the individual liver microsomal preparations (data not shown), the pooled preparation designated as CYP3A5 expressors (CYP3A5+) contained a low amount, while the pool designated as CYP3A5 non-expressors (CYP3A5-) contained a high amount, of CYP3A4 immunoreactive protein (Fig. 1) HLM, respectively). For both HLMs, the simple noncompetitive inhibition model best described the fluconazole-midazolam interaction. The K i of fluconazole was slightly higher in the CYP3A5+ compared to the CYP3A5-HLM (Fig. 2 and Table 1 ).
This article has not been copyedited and formatted. The final version may differ from this version. (Table 1) , consistent with the previous report (Gibbs et al., 1999) . The K i s obtained from the rCYP3As were roughly concordant (within 2-fold) with the corresponding values obtained from HLM.
With erythromycin as the substrate, the IC 50 for fluconazole was slightly lower in the CYP3A5+ HLM compared to the CYP3A5-HLM (Fig. 3 , Table 1 ). In contrast, the IC 50 obtained from rCYP3A5 was 3.5 times higher than that obtained from rCYP3A4 (Table 1 ). The IC 50 obtained from rCYP3A4 was similar to that with CYP3A5-HLM, while the IC 50 obtained from rCYP3A5 was 6.5-fold higher than that obtained from CYP3A5+ HLM (Table 1) .
Influence of CYP3A5 genotype on the extent of inhibition of CYP3A activity in healthy volunteers. To assess whether CYP3A5 expression influences the extent of CYP3A inhibition by fluconazole in vivo, a human volunteer study was conducted utilizing the same CYP3A probes. Because both probe drugs were given intravenously, the interaction with fluconazole was assumed to reflect primarily inhibition of hepatic CYP3A.
Fluconazole was rapidly absorbed, reaching a peak concentration within 2-3 hrs after oral administration. Importantly, because midazolam and the ERMBT were administered 1.5-2 hrs after fluconazole was administered, the fluconazole concentration was near or at its peak at the time the CYP3A probes were given (Fig. 4) . With midazolam as the probe, in the absence of fluconazole, the AUC and Cl of midazolam were similar among the three genotypic groups Fig. 4) . Correspondingly, midazolam Cl was significantly decreased by fluconazole within each genotypic group (p < 0.001), with the percent decrease being greatest in the CYP3A5*1 non-carriers ( Table 2) 
DISCUSSION
A growing body of in vitro data has demonstrated that CYP3A5 is less susceptible (more resistant) than CYP3A4 to inhibition by some therapeutic agents (Gibbs et al., 1999; Jones et al., 1999; McConn et al., 2004; Wang Y et al., 2005) . Because CYP3A5 can represent a significant portion of total hepatic CYP3A in some individuals (Kuehl et al., 2001; Lin et al., 2002), and CYP3A5 genotype can significantly influence the disposition of some CYP3A
substrates in vivo (e.g., saquinavir, tacrolimus, sirolimus, alprazolam) (Andersson et al., However, like with midazolam, the inhibitory difference was less profound than that with recombinant enzymes (IC 50 s of 350 and 100 µ M for rCYP3A5 and rCYP3A4, respectively).
Assuming that HLM represented the more clinically relevant system, the corresponding data were used to predict the effect of CYP3A5 genotype on the hepatic CYP3A-mediated interaction between fluconazole and the two probe substrates in vivo.
As predicted by HLM, the (inferred) presence of CYP3A5 lowered the inhibitory potency of fluconazole towards midazolam systemic clearance in healthy volunteers. The average K i , iv for homozygous CYP3A5*1 carriers was 85% higher than that for the noncarriers and was comparable to the ~70% difference observed in HLM. The ratio of the in vitro K i to the K i,iv (RK i ) was at or near unity for both the CYP3A5-and CYP3A5+ groups (1.0 and 1.2, respectively), 
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24 function (Venkatakrishnan et al., 2000) . Despite the modest underprediction of the magnitude of the ERMBT-fluconazole interaction, the data did predict the lack of influence of CYP3A5 genotype on the interaction, substantiating HLM as the preferred enzyme system to predict the inhibitory effect in vivo. Indeed, it is virtually impossible to predict the combined inhibitory effect toward CYP3A4 and CYP3A5 in vivo using recombinant enzymes because the relative expression of each enzyme varies considerably between individuals , and the intrinsic clearances between the two enzymes for different substrates can vary (Huang et al., 2004; McConn et al., 2004) . (Andersson et al., 2005; Thervet et al., 2005) , and interactions between tacrolimus and fluconazole, as well as other, more potent azole antifungal agents (ketoconazole and itraconazole) have been documented (Venkatakrishnan et al., 2000) . More recently, the hepatic clearance of the chemotherapeutic agent vincristine was estimated to be 5-fold greater in CYP3A5 high expressors compared to CYP3A5 low expressors based on results from HLM with known CYP3A4 and CYP3A5 content 
